1. Home
  2. BTBT vs PRTA Comparison

BTBT vs PRTA Comparison

Compare BTBT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bit Digital Inc.

BTBT

Bit Digital Inc.

HOLD

Current Price

$1.31

Market Cap

569.7M

Sector

Finance

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$9.97

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTBT
PRTA
Founded
2015
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
569.7M
539.9M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
BTBT
PRTA
Price
$1.31
$9.97
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$6.00
$19.00
AVG Volume (30 Days)
15.7M
508.2K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$113,560,320.00
$814,000.00
Revenue This Year
$89.54
$1,111.38
Revenue Next Year
$48.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.10
N/A
52 Week Low
$1.25
$4.32
52 Week High
$4.55
$11.69

Technical Indicators

Market Signals
Indicator
BTBT
PRTA
Relative Strength Index (RSI) 34.46 60.91
Support Level $1.25 $9.69
Resistance Level $2.43 $10.37
Average True Range (ATR) 0.09 0.40
MACD -0.01 0.11
Stochastic Oscillator 14.29 93.38

Price Performance

Historical Comparison
BTBT
PRTA

About BTBT Bit Digital Inc.

Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: